Literature DB >> 2908099

Intellectual impairment in Parkinson's disease: clinical, pathologic, and biochemical correlates.

J L Cummings1.   

Abstract

The prevalence of overt dementia in 27 studies representing 4,336 Parkinson's disease (PD) patients was 39.9%. The studies reporting the highest incidence of intellectual impairment (69.9%) used psychologic assessment techniques, whereas studies identifying the lowest prevalence of dementia (30.2%) depended on nonstandardized clinical examinations. Neuropsychologic investigations reveal that PD patients manifest impairment in memory, visuospatial skills, and set aptitude. Language function is largely spared. Intellectual deterioration in PD correlates with age, akinesia, duration, and treatment status. Neuropathologic and neurochemical observations demonstrate that PD is a heterogeneous disorder: the classic subcortical pathology with dopamine deficiency may be complicated by atrophy of nucleus basalis and superimposed cortical cholinergic deficits, and a few patients have the histopathologic hallmarks of Alzheimer's disease. Mild intellectual loss occurs with the classic pathology, and the more severe dementia syndromes have cholinergic alterations or Alzheimer's disease. Thus, PD includes several syndromes of intellectual impairment with variable pathologic and neurochemical correlates.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 2908099     DOI: 10.1177/089198878800100106

Source DB:  PubMed          Journal:  J Geriatr Psychiatry Neurol        ISSN: 0891-9887            Impact factor:   2.680


  32 in total

1.  Neuropsychology, neuroimaging or motor phenotype in diagnosis of Parkinson's disease-dementia: which matters most?

Authors:  Francesca Di Biasio; Nicola Vanacore; Alfonso Fasano; Nicola Modugno; Barbara Gandolfi; Francesco Lena; Giovanni Grillea; Sara Pietracupa; Giovanni Caranci; Stefano Ruggieri
Journal:  J Neural Transm (Vienna)       Date:  2011-12-13       Impact factor: 3.575

Review 2.  Neuropsychiatric non-motor aspects of Parkinson's disease.

Authors:  B R Thanvi; S K Munshi; N Vijaykumar; T C N Lo
Journal:  Postgrad Med J       Date:  2003-10       Impact factor: 2.401

Review 3.  [Diagnosis and clinical therapy for Parkinson's disease].

Authors:  S Wenzel; B Mollenhauer; C Trenkwalder
Journal:  Nervenarzt       Date:  2006-12       Impact factor: 1.214

4.  Cerebral microbleeds in patients with Parkinson's disease.

Authors:  Jee Hyun Ham; Han Yi; Mun Kyung Sunwoo; Jin Yong Hong; Young H Sohn; Phil Hyu Lee
Journal:  J Neurol       Date:  2014-06-12       Impact factor: 4.849

5.  Altered expression of vesicular glutamate transporters VGLUT1 and VGLUT2 in Parkinson disease.

Authors:  Alireza Kashani; Catalina Betancur; Bruno Giros; Etienne Hirsch; Salah El Mestikawy
Journal:  Neurobiol Aging       Date:  2006-03-24       Impact factor: 4.673

Review 6.  Lewy body and parkinsonian dementia: common, but often misdiagnosed conditions.

Authors:  Brit Mollenhauer; Hans Förstl; Günther Deuschl; Alexander Storch; Wolfgang Oertel; Claudia Trenkwalder
Journal:  Dtsch Arztebl Int       Date:  2010-10-01       Impact factor: 5.594

Review 7.  The neurobiology and neural circuitry of cognitive changes in Parkinson's disease revealed by functional neuroimaging.

Authors:  Nicola J Ray; Antonio P Strafella
Journal:  Mov Disord       Date:  2012-10-04       Impact factor: 10.338

8.  Does CSF p-tau181 help to discriminate Alzheimer's disease from other dementias and mild cognitive impairment? A meta-analysis of the literature.

Authors:  Wei Tang; Qiong Huang; Yu-You Yao; Yan Wang; Yi-Le Wu; Zheng-Yu Wang
Journal:  J Neural Transm (Vienna)       Date:  2014-05-10       Impact factor: 3.575

9.  Associations between cognitive and gait performance during single- and dual-task walking in people with Parkinson disease.

Authors:  Elizabeth L Stegemöller; Jonathan P Wilson; Audrey Hazamy; Mack C Shelley; Michael S Okun; Lori J P Altmann; Chris J Hass
Journal:  Phys Ther       Date:  2014-02-20

10.  Cerebrospinal α-synuclein in α-synuclein aggregation disorders: tau/α-synuclein ratio as potential biomarker for dementia with Lewy bodies.

Authors:  Franc Llorens; Matthias Schmitz; Daniela Varges; Niels Kruse; Nadine Gotzmann; Karin Gmitterová; Brit Mollenhauer; Inga Zerr
Journal:  J Neurol       Date:  2016-08-20       Impact factor: 4.849

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.